{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:22:36Z","timestamp":1791638556651,"version":"4.3.4"},"reference-count":43,"publisher":"Massachusetts Medical Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Evidence"],"published-print":{"date-parts":[[2022,6,28]]},"DOI":"10.1056\/evidoa2200006","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T17:00:32Z","timestamp":1652461232000},"source":"Crossref","is-referenced-by-count":227,"title":["Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities"],"prefix":"10.1056","volume":"1","author":[{"given":"Arnon P.","family":"Kater","sequence":"first","affiliation":[{"name":"Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, on behalf of the HOVON CLL Working Group, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Follows","sequence":"additional","affiliation":[{"name":"Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"St James\u2019s Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"Albert Schweitzer Hospital, Dordrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Benjamini","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[{"name":"Universitaire Ziekenhuizen Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Osterborg","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital, Stockholm"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Medical University of \u0141\u00f3d\u017a, Copernicus Memorial Hospital, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Simkovic","sequence":"additional","affiliation":[{"name":"University Hospital Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Voloshin","sequence":"additional","affiliation":[{"name":"Russian Scientific Research Institute of Hematology and Transfusiology, St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vorobyev","sequence":"additional","affiliation":[{"name":"S.P. Botkin Moscow City Clinical Hospital, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qin","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Steele","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Schuier","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Baeten","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donne Bennett","family":"Caces","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[{"name":"Rigshospitalet Copenhagen University Hospital, Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","unstructured":"National Cancer Institute Surveillance Research Program. SEER*Explorer: An interactive website for SEER cancer statistics. 2021 (https:\/\/seer.cancer.gov\/explorer\/)."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219853030"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327481502204s04"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595"},{"key":"e_1_3_5_9_2","unstructured":"National Comprehensive Cancer Network. NCCN 2018 guidelines: chronic lymphocytic leukemia\/small lymphocytic lymphoma version 5. 2018 (https:\/\/www2.tri-kobe.org\/nccn\/guideline\/hematologic\/english\/csll.pdf)."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw359"},{"key":"e_1_3_5_11_2","volume-title":"Prescribing information.","unstructured":"Imbruvica (ibrutinib). Prescribing information. Horsham, PA: Janssen Biotech Inc. and Sunnyvale, CA: Pharmacyclics LLC, 2020."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_5_16_2","unstructured":"National Comprehensive Cancer Network. NCCN 2022 guidelines: chronic lymphocytic leukemia\/small lymphocytic lymphoma version 5. 2022 (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf)."},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_5_18_2","volume-title":"Prescribing information.","unstructured":"Venclexta (venetoclax tablets). Prescribing information. South San Francisco, CA: AbbVie Inc. and North Chicago, IL: Genentech USA Inc., 2020."},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004326"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0781"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00429-z"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004861"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311846111"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1649"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008608"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7501"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_5_34_2","unstructured":"Adaptive Biotechnologies. clonoSEQ assay technical summary. 2022 (https:\/\/www.clonoseq.com\/technical-summary\/)."},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313"},{"key":"e_1_3_5_36_2","unstructured":"ECOG-ACRIN Cancer Research Group. ECOG performance status scale. 1982 (https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\/)."},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_287_18"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.122"},{"key":"e_1_3_5_40_2","volume-title":"Prescribing information.","unstructured":"Calquence (acalabrutinib). Prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2019."},{"key":"e_1_3_5_41_2","volume-title":"Prescribing information.","unstructured":"Brukinsa (zanubrutinib). Prescribing information. San Mateo, CA: BeiGene Ltd., 2021."},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318259"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192328"},{"key":"e_1_3_5_44_2","unstructured":"ClinicalTrials.gov. Ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukaemia (CLL) (CLL17). 2020 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608318)."}],"container-title":["NEJM Evidence"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T09:30:35Z","timestamp":1656408635000},"score":1,"resource":{"primary":{"URL":"https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2200006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6,28]]}},"alternative-id":["10.1056\/EVIDoa2200006"],"URL":"https:\/\/doi.org\/10.1056\/evidoa2200006","relation":{},"ISSN":["2766-5526"],"issn-type":[{"value":"2766-5526","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,28]]}}}